Guest Editors
Prof. Edward M. Messing
Email: Edward_Messing@urmc.rochester.edu
Affiliation: Departments of Urology, Oncology and Pathology, University of Rochester, Rochester, New York 14642, USA
Homepage:
Research Interests: early detection and screening of bladder cancer, molecular pathogenesis of urothelial carcinoma, innovative intravesical therapies to prevent recurrence, clinical trial design in urologic oncology, translational and implementation science, diagnosis and treatment of genitourinary cancers
Dr. Kamil Malshy
Email: Kamil_malshy@URMC.rochester.edu
Affiliation: Department of Urology, University of Rochester, Rochester, 14627, United States
Homepage:
Research Interests: biomarkers and risk stratification in prostate cancer, innovative treatments in non-muscle-invasive bladder cancer (nmibc), decision-making for geriatric and frail patients with urologic malignancies: clinical trials methodology, health disparities and access to care
Summary
Bladder and prostate cancers remain two of the most prevalent and impactful malignancies in urologic oncology, posing ongoing challenges in early detection, risk stratification, and therapeutic management. Recent advances in molecular diagnostics, imaging technologies, and treatment strategies—particularly within the framework of clinical trials—are reshaping standards of care. With evolving insights into tumor biology, patient-centered trial design, and emerging targeted and immunotherapeutic options, the field stands at a pivotal point for translating innovation into improved outcomes.
This Special Issue aims to showcase cutting-edge research and clinical trial efforts in bladder and prostate cancer, emphasizing translational discoveries, biomarker-driven diagnostics, and novel therapeutic approaches. We welcome contributions spanning basic science, translational research, clinical studies, and implementation science that advance precision medicine and improve oncologic care. The issue will highlight interdisciplinary efforts to refine patient selection, optimize treatment pathways, and address disparities in clinical trial access and outcomes.
Suggested Themes
· Urinary and tissue biomarkers for diagnosis and risk stratification in bladder and prostate cancers
· Innovations in intravesical therapy and systemic treatment for NMIBC and MIBC
· Advancements in imaging and AI applications for cancer detection and surveillance
· Hormonal and immunotherapeutic strategies in advanced prostate cancer
· Surgical innovation and outcomes in radical prostatectomy and cystectomy
· Clinical trials in urologic oncology
· Health equity and disparities in access to clinical trials and advanced therapies
· Geriatric and frailty-informed decision-making in urologic cancer care
This Special Issue aims to foster collaboration among urologic oncologists, medical and radiation oncologists, clinical trialists, molecular biologists, and healthcare policy experts. By integrating multidisciplinary perspectives, we hope to accelerate the translation of discovery into practice and improve care for patients facing bladder and prostate cancers.
Keywords
bladder cancer, prostate cancer, urologic oncology, clinical trials, biomarkers, risk stratification, immunotherapy, hormonal therapy, minimally invasive surgery, translational research
Login
Register
Submit a Paper
Propose a Special lssue